title: Author reply: To PMID 23415776.
authors.forename: Namrata
authors.initials: N
authors.lastname: Sharma
authors.forename: Manik
authors.initials: M
authors.lastname: Goel
authors.forename: Shubha
authors.initials: S
authors.lastname: Bansal
authors.forename: Prakashchand
authors.initials: P
authors.lastname: Agarwal
authors.forename: Jeewan
authors.initials: J
authors.lastname: Titiyal
authors.forename: Ashish
authors.initials: A
authors.lastname: Upadhyaya
authors.forename: Rasik
authors.initials: R
authors.lastname: Vajpayee
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D002437:Cefazolin / Q000627:therapeutic use*; D003320:Corneal Ulcer / Q000188:drug therapy*; D015818:Eye Infections, Bacterial / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D011804:Quinolines / Q000627:therapeutic use*; D014031:Tobramycin / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D011804:Quinolines; D002437:Cefazolin; D014031:Tobramycin